Contrast‐Enhanced Cardiac Magnetic Resonance Imaging With a Manganese‐Based Alternative to Gadolinium for Tissue Characterization of Acute Myocardial Infarction
Authors:
- Benjamin P. BonnerBBBenjamin P. Bonner
- Salva R. YuristaSYSalva R. Yurista
- Jaume Coll‐FontJCJaume Coll‐Font
- Shi ChenSCShi Chen
- Robert A. EderRERobert A. Eder
- Anna N. FosterAFAnna N. Foster
- Khoi D. NguyenKNKhoi D. Nguyen
- Peter CaravanPCPeter Caravan
- Eric M. GaleEGEric M. Gale
- Christopher NguyenCNChristopher Nguyen
Open Access
- 18 April 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (8)
Abstract
Background: Late gadolinium enhancement cardiac magnetic resonance imaging is an effective and reproducible method for characterizing myocardial infarction. However, gadolinium‐based contrast agents are contraindicated in patients with acute and chronic renal insufficiency. In addition, several recent studies have noted tissue deposition of free gadolinium in patients who have undergone serial contrast‐enhanced magnetic resonance imaging. There is a clinical need for alternative forms of magnetic resonance imaging contrast agents that are acceptable in the setting of renal insufficiency. Methods and Results: Three days after 80 minutes of ischemia/reperfusion of the left anterior descending coronary artery, cardiac magnetic resonance imaging was performed to assess myocardial lesion burden using both contrast agents. Late gadolinium enhancement cardiac magnetic resonance imaging was examined 10 and 15 minutes after contrast injection. Contrast agents were administered in alternating manner with a 2‐ to 3‐hour washout period between contrast agent injections. Lesion evaluation and image processing were performed using Segment Medviso software. Mean infarct size and transmurality, measured using RVP‐001, were not different compared with those measured using late gadolinium enhancement images. Bland‐Altman analysis demonstrated a nominal bias of 0.13 mL (<1% of average total lesion volume) for RVP‐001 in terms of gross infarct size measurement. Conclusions: The experimental manganese‐based contrast agent RVP‐001 appears to be an effective agent for assessment of myocardial infarction location, size, and transmurality, and it may be useful as an alternative to gadolinium‐based agents.Keywords
This publication has 49 references indexed in Scilit:
- Manganese-based MRI contrast agents: past, present, and futureTetrahedron, 2011
- Cardiac imaging after myocardial infarctionEuropean Heart Journal, 2010
- Revisiting an old friend: manganese‐based MRI contrast agentsWIREs Nanomedicine and Nanobiotechnology, 2010
- Role of Cardiac Magnetic Resonance Imaging in the Detection of Cardiac AmyloidosisJACC: Cardiovascular Imaging, 2010
- Design and validation of Segment - freely available software for cardiovascular image analysisBMC Medical Imaging, 2010
- Biodistribution of gadolinium‐based contrast agents, including gadolinium depositionJournal of Magnetic Resonance Imaging, 2009
- Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular functionAmerican Heart Journal, 2006
- Motion‐corrected free‐breathing delayed enhancement imaging of myocardial infarctionMagnetic Resonance in Medicine, 2004
- Effect of Contrast Dose and Field Strength in the Magnetic Resonance Detection of Brain MetastasesInvestigative Radiology, 2003
- Mn‐DPDP enhancement patterns of hepatocellular lesions on MR imagesJournal of Magnetic Resonance Imaging, 1993